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Key messages
 ► Does blood group influence mortality in patients with 
critical illness?
 ► Intensive care patients with blood group AB ap-
peared to have a higher 90-day survival compared 
with other blood groups.
 ► This is the first study to describe an effect of blood 
group on survival following critical illness.
AbstrAct
background Predicting patient outcomes following critical 
illness is challenging. Recent evidence has suggested that 
patients with blood group AB are more likely to survive 
following major cardiac surgery, and this is associated with 
a reduced number of blood transfusions. However, there 
are no current data to indicate whether a patient’s blood 
group affects general intensive care outcomes.
Objective The objective of this study was to determine 
if ABO blood group affects survival in intensive care. The 
primary outcome measure was 90-day mortality with a 
secondary outcome measure of the percentage of patients 
receiving a blood transfusion.
Design Retrospective analysis of electronically collected 
intensive care data, blood group and transfusion data.
setting General intensive care unit (ICU) of a major 
tertiary hospital with both medical and surgical patients.
Patients All patients admitted to ICU between 2006 and 
2016 who had blood group data available.
Intervention None.
Measurements and main results 7340 patients were 
included in the study, blood group AB accounted for 
3% (221), A 41% (3008), B 10.6% (775) and O 45.4% 
(3336). These values are similar to UK averages. Baseline 
characteristics between the groups were similar. Blood 
group AB had the greatest survival benefit (blood group AB 
90-day survival estimate 76.75, 95% CI 72.89 to 80.61 
with the overall estimate 72.07, 95% CI 71.31 to 72.82) 
(log-rank χ2 16.128, p=0.001). Transfusion requirements 
were similar in all groups with no significant difference 
between the percentages of patients transfused (AB 
23.1%, A 21.5%, B 18.7%, O 19.9%, Pearson χ2 5.060 
p=0.167).
conclusion Although this is primarily a hypothesis 
generating study, intensive care patients with blood group 
AB appeared to have a higher 90-day survival compared 
with other blood groups. There was no correlation 
between blood group and percentage of patients receiving 
transfusion.
IntrODuctIOn
Predicting patient outcomes following critical 
illness is challenging. Personalised medicine, 
where a greater understanding of patients’ 
risks from genetic, environmental and social 
factors is becoming increasingly important 
and may allow better planning of therapy 
and outcomes.1 Although genetic variation 
is known to be one factor in determining 
survival following admission to intensive care, 
this can be difficult and costly to assess in clin-
ical practice.1
At the onset of critical illness, a logical and 
pragmatic approach is required to effectively 
manage patients. ABO blood group testing is 
a routine medical test that provides a rapid 
patient phenotype to the clinician. If ABO 
blood group impacts survival, it could provide 
a useful additional facet to stratifying risk. 
In addition, it may direct clinicians towards 
novel therapeutic interventions in the future.
The effect of ABO group has been anal-
ysed in multiple disease pathologies with 
differences noted in venous thromboem-
bolism,2 coronary artery disease3 and malig-
nancies including those of the pancreas and 
stomach.4–6 Recent evidence has suggested 
that patients with blood group AB are more 
likely to survive following major cardiac 
surgery and this is associated with a reduced 
number of blood transfusions.7 There may 
also be an influence on patient outcomes 
according to the gender and age of trans-
fused products.1
There is a body of evidence which demon-
strates that blood group AB has higher levels 
of von Willebrand factor (vWF) and factor 
VIII,8 9 making this group more pro-throm-
botic. While this may increase the risk of both 
arterial and venous thrombotic events,10 11 it 
may be beneficial in patient groups where 
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Table 1 Blood group in study compared with UK 
averages25
Group % in study % in UK
A 40.9 42
AB 3 4
B 10.6 10
O 45.4 44
Table 2 Baseline characteristics categorical level data with χ2 used and interval data one-way analysis of variance.
Characteristic Overall A AB B O P value
Number (%) n=7340 3008 (41.0%) 221 (3.0%) 775 (10.6%) 3336 (45.4%) –
Mean age, years (SD) 58.8 (17.2) 59.3 (17.1) 58 (16.6) 58.8 (17.3) 58.5 (17.3) 0.245
Female, % (n) 41.7% (3063) 41.7% (1255) 36.2% (80) 43.7% (339) 41.7% (3063) 0.508
BMI, mean (SD) 27.05 (6.4) 27.1 (6.3) 26.8 (6.8) 27 (7.2) 27.1 (6.2) 0.894
Surgery during admission, % (n) 46.3% (3399) 46.5% (1398) 41.6% (92) 44.6% (346) 46.9% (1563) 0.356
Days in hospital, mean (SD) 30.2 (45.2) 31.5 (53.0) 29.0 (28.1) 28.2 (37.2) 29.6 (39.9) 0.202
% Caucasian (n) 95.5% (7013) 97.1% (2922) 95.5% (211) 90.3% (700) 95.3% (3180) 0.000
APACHE score, mean (SD) 13.45 (7.86) 13.59 (7.87) 13.39 (7.62) 13.52 (8.26) 13.30 (7.77) 0.528
BMI, body mass index.
bleeding risks are high. In one study of more than 1100 
healthy volunteers, mean vWF antigen was lowest in 
blood group O (74.8 U/dL), followed by blood group A 
(105.9 U/dL), group B (116.9 U/dL) and finally group 
AB (123.3 U/dL).12 This increases the rate of significant 
bleeding in group O patients most notably in surgical 
procedures with a high risk of blood loss.13
Currently, there are no available data to indicate 
whether a patient’s blood group affects general intensive 
care outcomes.
The objective of the study was to determine if ABO 
blood group affects survival following admission to a 
general intensive care unit (ICU). The primary outcome 
measure was 90-day mortality with a secondary outcome 
measure of the percentage of patients receiving a blood 
transfusion during that hospital admission.
MAterIAls AnD MethODs
We performed a retrospective database analysis of all 
patients admitted to the ICU of a major tertiary University 
Hospital (both medical and surgical patients) between 
2006 and 2016 where ABO blood group data were avail-
able. Baseline characteristics for each blood group were 
collected including, age, gender, body mass index (BMI), 
surgery during admission, days in hospital, ethnicity and 
APACHE II score. Continuous baseline characteristics 
were evaluated using analysis of variance (ANOVA). A χ2 
test was used to determine equivalence of baseline char-
acteristics of discrete variables.
Patients’ primary ABO blood group status was collected 
along with any blood product transfusions they received 
during their hospital stay.
The primary outcome for the study was 90-day hospital 
survival. Survival analysis was performed using the time 
from hospital admission to discharge. If patients had a 
hospital stay longer than 90 days, data were censored 
to 90 days. The secondary outcome measure was the 
percentage of each blood group that received any blood 
product transfusion.
Ninety-day survival was estimated by Kaplan-Meier 
plots, with binary logistic regression used to calculate 
odds ratios between different blood groups. Binary 
logistic regression with Pearson’s χ2 test was used to 
determine OR between blood groups. ABO blood groups 
were individually compared and then pooled to compare 
AB versus non-AB blood groups. A subgroup analysis 
was performed on patients that had surgery during their 
admission.
Intensive care data were merged with individual patient 
transfusion data using R (V.1.0.136, 2016, R Studio). The 
combined data were exported to SPSS (V.23.0, IBM) for 
statistical evaluation. The study was granted scientific 
approval by Wales research ethics review service.
Patient and public involvement
As this was a retrospective database study, there was no 
individual patient or public involvement. However, it 
does conform with the James Lind top ten priority setting 
from public groups including ‘How can we predict who 
will benefit from intensive care before admission and 
during treatment in the ICU?’
results
During January 2010 to January 2016, 7906 patients were 
admitted to the ICU with blood group data available 
for 7340. Blood group AB accounted for 3% (221), A 
41% (3008), B 10.6% (775) and O 45.4% (3336). These 
values are similar to UK averages. The mean age was 
58.8±17.2 years; 41.7% of patients (n=3063) were female 
and average BMI was 27.05±6.4 (table 1). Admission 
APACHE score was 13.45±7.86 and the percentage of 
patients undergoing surgery during their admission was 
46.3% (n=3399). Baseline characteristics were statistically 
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Figure 1 Kaplan-Meier survival plot for 90-day intensive 
care unit survival by ABO blood group.
Figure 2 Kaplan-Meier survival plot for 90-day intensive 
care unit survival for AB compared with pooled non-AB 
blood groups.
Figure 3 Kaplan-Meier survival plot for 90-day ICU 
survival by ABO blood group in subgroup of patients 
undergoing surgery during admission.
Table 3 Transfusion requirements per blood group
Group
% of blood group transfused 
(n)
A 21.5 (648)
AB 23.1 (51)
B 18.7 (145)
O 19.9 (665)
Total 20.6 (1509)
similar across the blood groups except for the ethnicity of 
the groups with blood group B having fewer Caucasians 
90.3% compared with an average of 95.5% (table 2).
Blood group AB had the greatest survival difference 
when assessing individual blood groups (figure 1) (blood 
group AB 90-day survival estimate 76.75, 95% CI 72.89 
to 80.61 with the overall estimate 72.07, 95% CI 71.31 to 
72.82) (log-rank χ2 16.128, p=0.001).
When pooling blood group data (figure 2), Kaplan-
Meier analysis showed blood group AB (n=221) to have 
improved survival compared with non-AB blood groups 
(n=7119) (blood group AB 90-day survival estimate 
76.75, 95% CI 72.89 to 80.61 non-AB groups 71.92, 95% 
CI 71.15 to 72.69) (log-rank χ2 3.890, p=0.049).
Compared with AB, non-AB groups had an OR for 
death of 1.413 (95% CI 1.002 to 1.992, p=0.049). Blood 
group AB also showed a trend towards improved 90-day 
survival in the subgroup (n=3399) of patients who under-
went surgery during their hospital admission (figure 3) 
(blood group AB 83.89, 95% CI 79.64 to 88.14 with the 
overall estimate 78.26, 95% CI 77.32 to 79.20), however 
this benefit was not statistically significant (log-rank χ2 
5.537, p=0.136).
Transfusion requirements were similar in all groups 
(table 3) with no significant difference between the 
percentages of patients transfused (AB 23.1%, A 21.5%, 
B 18.7%, O 19.9%, Pearson χ2 5.060 p=0.167).
DIscussIOn
This is the first study to describe an effect of blood group 
on survival following critical illness. We observed patients 
with blood group AB to have an improved 90-day survival 
following admission to the ICU.
ABO blood group system is the major component 
of categorising a patients’ blood type. The ABO blood 
group system was first described by Landsteiner in 1900; 
despite more than 300 antigens identified on red blood 
cells (RBC), the ABO blood group system remains the 
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most significant in cases of mismatch.14 The ABO system 
of blood grouping refers to antibodies against glycopep-
tide antigens present on RBC, and other cells including 
sensory neurons, platelets and endothelium.15 An 
isolated gene on chromosome 9 at the loci 9q34.1-q34.2 
determines ABO blood group.16 17 This locus encodes a 
glycosyltransferase that produces N-acetylgalactosamine 
(A antigen) and D-galactose (B antigen) for the surface 
of the RBC.8 These antigens are formed from a precursor 
antigen H encoded on chromosome 19 (loci 19q13.3).8 
The immune system then forms antibodies against the 
ABO blood group antigens not found in the individual.
ABO blood group has been implicated as a risk factor 
in both venous thromboembolism2 and coronary artery 
disease.3 One proposed mechanism for the varying clin-
ical outcomes in patients is the different amounts of 
vWF and factor VIII per blood group. ABO blood group 
plays an important role in determining levels of vWF and 
factor VIII in the circulation.18 vWF is an adhesive glyco-
protein which acts as a key haemostatic agent by binding 
with structures involved in the coagulation cascade 
particularly factor VIII, exposed collagen and platelets.19 
It is known that factor VIII levels are primarily affected by 
vWF as the two form a complex where vWF is the carrier, 
however recent evidence has shown that ABO blood 
group has an additional effect on Factor VIII levels which 
is independent to vWF.9
Individual levels of vWF vary widely. Blood group O 
demonstrate lower levels of vWF and factor VIII and this 
is thought to have a functional effect on thrombosis with 
a reduced risk.20 Higher levels of factor VIII and vWF are 
associated with higher levels of venous thromboembo-
lism and arterial disease, particularly myocardial infarc-
tion.2 21 Blood group O levels of vWF are up to 25% lower 
than non-O blood groups.21 22 Among the non-O blood 
groups, blood group AB has the highest levels of vWF.23 
Blood group AB may therefore represent a higher risk 
for thrombosis under normal conditions, however this 
may lead to a survival benefit under periods of physio-
logical stress such as surgery or critical illness where a 
prothrombotic state is potentially beneficial.
There are a number of limitations to the current 
study. The data available in this retrospective analysis 
did not allow us to perform covariate adjusted analysis 
using pre-existing conditions, critical care manage-
ment or specific reasons for current admission. This is 
a constraint in an observational study of this type which 
may be addressed in future studies with more compre-
hensive datasets.
We hypothesised that survival of blood group AB 
patients may be related to levels of vWF/Factor VII but 
these were not measured. There was no statistical differ-
ence in the numbers of patients receiving blood trans-
fusion in any of the groups, however we do not know 
if there were differences in the number of units trans-
fused or indeed other blood products. It is also possible 
that the number of patients in our study was too small 
to detect a difference in transfusion requirements. This 
is in contrast to patients undergoing cardiac surgery,7 as 
this population of patients is more likely to receive blood 
transfusions and therefore differences may be more 
evident. The relevance of vWF/FVII in modulating the 
observed association is only speculative and other mech-
anisms are described in the literature.24
The retrospective study design limits the conclusions 
we can draw from this study, as we can suggest there is 
an association between survival and AB blood group but 
no causation. In addition, using a 90-day measure for 
survival means we cannot draw long-term outcomes from 
our study.
This is the first study to assess the effects of blood 
group on patients with critical illness. This work supports 
the findings of Welsby et al that patients with blood group 
AB are more likely to survive cardiac surgery.7 There 
are a number of overlaps between the two population 
groups, however our population was in a general ICU 
setting. As such there was a greater variety of aetiologies 
of critical illness with both medical and surgical cohorts 
of patients included. A subgroup analysis showed that 
surgical patients in the ICU had a greater survival benefit 
of being blood group AB, however this was not statisti-
cally significant.
Our study used 10 year data at a single centre. The 
patients included in our study was representative of the 
distribution of ABO blood groups within the UK, blood 
group AB is a relatively small proportion accounting for 
3% in our study (n=221) and across the UK.25 It is also 
important to highlight that we compared results based 
on the phenotype of patients not their individual blood 
group genotype. This is in keeping with clinical prac-
tice and the literature on ABO blood group and clinical 
outcomes.
It is likely that there are a wide variety of genetic factors 
that are interlinked that help to determine an individu-
al’s outcome from disease. However, it can be difficult 
to elicit an individual patient’s genetic risk, particularly 
within clinical practice. ABO blood typing is a ubiqui-
tous clinical test that provides a window onto the genetic 
nature of disease and variations in patient outcome. It 
seems likely that ABO blood group is interlinked with 
other genetic and patient factors to determine differ-
ences in prevalence and outcome from varying disease 
pathologies. Future studies could measure vWF/FVII in 
different blood groups and a future therapeutic interven-
tion based on mechanistic studies may include targeted 
transfusion or use of drugs such as desmopressin.
cOnclusIOns
Intensive care patients with blood group AB have a signif-
icantly higher 90-day survival compared with other blood 
groups. There was no correlation between blood group 
and percentage of patients receiving transfusion. Blood 
group AB is relatively rare accounting for 3% of the 
study population and therefore our study may have been 
underpowered to determine this bleeding risk. Improved 
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survival outcomes in blood group AB are a promising 
area for further study.
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